Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
36 participants
OBSERVATIONAL
2009-10-31
2010-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Concerning this, some studies suggest that non-demented PD patients may suffer from a voluntary selective visual attention orienting deficit, showing a reduced skill in focusing upon one target, and may be easily distracted from irrelevant but salient stimuli, with a consequent negative impact on their physical health, social interactions and quality of life.
Up to now, the evidence of the role of the basal-ganglia system in modulating visual attention functions is poor and indirect and the effects of dopaminergic and subthalamic nucleus (STN) stimulation (two usual and effective treatments in PD) on attention performances are controversial.
The main objectives of the project are: 1) to assess the visual selective attention as well as the distractibility in PD patients; 2) to study the effects of patient's usual antiparkinsonian treatments, that is dopaminergic and STN stimulation, on visual attention performances.
Secondly, from a clinical and neurophysiologic point of view, the investigators want to study the respective role of the dopaminergic pathways and the sensorimotor and associative/limbic cortico-basal ganglia loops passing across the STN in the visual attention performances.
To precisely answer the objectives of the protocol, the investigators will record the performances of participants during the administration of 3 computerized tests, which are suitable to study visual attention, decision making and motor performances.
The investigators will compare the performances on the computerized tests of two groups of PD patients, one evaluated in different sets of electrical (without stimulation, or selective stimulation of the sensorimotor or associative/limbic part of the STN) stimulation, the other in different conditions of medication (with or without dopaminergic treatment) with those of a group of healthy subjects.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
group #1
Parkinson's disease patients at a disease's stage characterized by motor complications
Recording during computerized tests
Patients will perform more than one experimental session. In each experimental session 3 computerized tasks, which are suitable to study visual attention, decision making and motor performances will be presented. During these tests, participants have to responds the most quickly and accurately possible to the appearance on a computer display of a predetermined target stimuli, presented alone or in an array of signals.
The computerized tests are administered in two different conditions of medication: with or without dopaminergic treatment, corresponding to two different experimental sessions.
group #2
Parkinson's disease patients treated by subthalamic nucleus deep brain stimulation.
Recording during computerized tests
Patients will perform more than one experimental session. In each experimental session 3 computerized tasks, which are suitable to study visual attention, decision making and motor performances will be presented. During these tests, participants have to responds the most quickly and accurately possible to the appearance on a computer display of a predetermined target stimuli, presented alone or in an array of signals. The computerized tests are administered in three different sets of electrical (without stimulation, or selective stimulation of the sensorimotor or associative/limbic part of the subthalamic nucleus) stimulation, corresponding to three different experimental sessions.
group #3
healthy controls
Recording during computerized tests
Participants will perform more than one experimental session. In each experimental session 3 computerized tasks, which are suitable to study visual attention, decision making and motor performances will be presented. During these tests, participants have to responds the most quickly and accurately possible to the appearance on a computer display of a predetermined target stimuli, presented alone or in an array of signals.The computerized tests are administered twice (in two different experimental sessions) to verify the performance repeatability.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Recording during computerized tests
Patients will perform more than one experimental session. In each experimental session 3 computerized tasks, which are suitable to study visual attention, decision making and motor performances will be presented. During these tests, participants have to responds the most quickly and accurately possible to the appearance on a computer display of a predetermined target stimuli, presented alone or in an array of signals.
The computerized tests are administered in two different conditions of medication: with or without dopaminergic treatment, corresponding to two different experimental sessions.
Recording during computerized tests
Patients will perform more than one experimental session. In each experimental session 3 computerized tasks, which are suitable to study visual attention, decision making and motor performances will be presented. During these tests, participants have to responds the most quickly and accurately possible to the appearance on a computer display of a predetermined target stimuli, presented alone or in an array of signals. The computerized tests are administered in three different sets of electrical (without stimulation, or selective stimulation of the sensorimotor or associative/limbic part of the subthalamic nucleus) stimulation, corresponding to three different experimental sessions.
Recording during computerized tests
Participants will perform more than one experimental session. In each experimental session 3 computerized tasks, which are suitable to study visual attention, decision making and motor performances will be presented. During these tests, participants have to responds the most quickly and accurately possible to the appearance on a computer display of a predetermined target stimuli, presented alone or in an array of signals.The computerized tests are administered twice (in two different experimental sessions) to verify the performance repeatability.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to tolerate a prolonged condition without medication
* Levodopa response \> 30% (for group #1)
* Self-declared normal or corrected to normal vision
* At least one contact lead in the sensorimotor part and another contact in the associativelimbic part of the STN (for group #2).
* Patients with a healthy social security affiliation
* Able to give and sign the informed consent
* Self-declared neurologically healthy subjects,
* Self-declared normal or corrected to normal vision
* No psychotropic or neurotrophic drugs intake
* Subjects with a healthy social security affiliation
* Able to give and sign the informed consent
Exclusion Criteria
* Fertile women not using adequate contraceptive methods
* Women who are pregnant or breast feeding
* Severe cognitive impairment
* Severe frontal executive functions impairment
* Actual psychotic disorders
* Major depression
* Motivation impairment
* Any medical or psychological problems which may interfere with a smooth conduction of the study protocol
* Significant deficiency in red-green color discrimination
* Drug or alcohol addiction
Healthy controls: group #3
* Patients under guardianship, interdicted, or under administrative measures and legal constraints
* Fertile women not using adequate contraceptive methods
* Women who are pregnant or breast feeding
* Severe cognitive impairment
* Severe frontal executive functions impairment
* Actual psychotic disorders
* Major depression
* Motivation impairment
* Any medical or psychological problems which may interfere with a smooth conduction of the study protocol
* Significant deficiency in red-green color discrimination
* Drug or alcohol addiction
21 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Grenoble
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Unité des Troubles du Mouvement, Clinique de Neurologie, Grenoble University Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pierre POLLAK, Professor
Role: PRINCIPAL_INVESTIGATOR
Unité des Troubles du Mouvement, Clinique de Neurologie, Grenoble University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Unité des Troubles du Mouvement, Clinique de Neurologie, Grenoble University Hospital
Grenoble, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0914
Identifier Type: -
Identifier Source: org_study_id